Modified H7 hemagglutinin glycoprotein of the Influenza A/Shanghai/2/2013 H7 sequence
The present invention is directed to a sequence modification of the H7 hemagglutinin glycoprotein of the Influenza A/Shanghai/2/2013 H7 sequence together with vaccines derived therefrom. In addition, the invention further comprises method for improving the efficacy of vaccine antigens by modifying T cell epitopes.
1. A polypeptide comprising the entire amino acid sequence of SEQ ID NO: 2 or a fragment thereof provided that said fragment contains SEQ ID NO: 3.
2. A vaccine comprising one or more polypeptides comprising the entire amino acid sequence of SEQ ID NO: 2 or a fragment thereof provided that said fragment contains SEQ ID NO: 3.
3. The vaccine of claim 2 , further comprising an adjuvant.
4. A composition comprising one or more polypeptides comprising the entire amino acid sequence of SEQ ID NO: 2 or a fragment thereof provided that said fragment contains SEQ ID NO: 3.
5. A method for vaccinating against influenza comprising administering to a subject a composition comprising one or more polypeptides comprising the entire amino acid sequence of SEQ ID NO: 2 or a fragment thereof provided that said fragment contains SEQ ID NO: 3.
6. The method of claim 5 , wherein the composition further comprises an adjuvant.
7. The method of claim 5 , wherein the influenza is avian-origin H7N9 influenza.
8. A method for enhancing an anti-H7 antibody response comprising administering a composition comprising one or more polypeptides comprising the entire amino acid sequence of SEQ ID NO: 2 or a fragment thereof provided that said fragment contains SEQ ID NO: 3.
9. The method of claim 8 , wherein the composition further comprises an adjuvant.
10. A kit for enhancing an anti-H7 antibody response in a subject, said kit comprising one or more polypeptides comprising the amino acid sequence of SEQ ID NO: 2 or a fragment thereof provided that said fragment contains SEQ ID NO: 3.
11. The kit of claim 10 , further comprising an adjuvant.